Strategic Transaction Benefits and Improves
Aquaculture Health and Performance
Merck Animal Health, a division of Merck & Co., Inc.,
Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of
its acquisition of Vaki, a leader in fish farming and wild fish
conservation monitoring equipment and real-time video monitoring
technology to advance fish health and welfare, from Pentair
(NYSE:PNR), a leading global water treatment company.
Today’s announcement further positions Merck Animal Health as a
global leader in broadening its aquaculture portfolio by expanding
into complementary fish farming and conservation areas to generate
outcomes with precision farming and fish welfare solutions, which
complement its existing portfolio of vaccines and pharmaceuticals.
Vaki will be a leading brand under the Biomark business within
Merck Animal Health, focused on a range of equipment, products and
technology for fish counting and size estimation from freshwater to
saltwater rearing, while collecting data and analytics for each
stage of fish production.
“Animal health intelligence and enhanced technology play an
increasingly important role in animal health and care, providing
access to real-time actionable data and insights to help, improve
or enhance animal management and health outcomes,” said Rick
DeLuca, president, Merck Animal Health. “We continue to execute
upon our strategy to expand and add breadth to our portfolio and
its technology. We are at the technological forefront of shaping
the future of animal health through our commitment to leveraging
our scientific capabilities and expertise through comprehensive
solutions to manage the health and well-being of animals. We are
excited to take this step forward with Vaki, as we add leading
technology and services, which extend the range of solutions in
aquaculture we can provide to our customers.”
Karl Frykman, executive vice president and chief operating
officer at Pentair, said, “We are proud of Vaki’s transformation
over the past years. Vaki has significant potential to continue to
spearhead development in the aquaculture industry and we believe
that Merck Animal Health is an ideal partner to support the next
stage of its growth.”
Biomark specializes in electronic identification technology used
in fisheries, wildlife and aquaculture research, including product
sales, custom manufacturing, installation and extensive data
management and analysis.
In April 2019, Merck Animal Health announced the completion of
its acquisition of Antelliq Corporation and its brands, Allflex
Livestock Intelligence, Sure Petcare and Biomark, as leaders in
emerging digital technology with animal identification, animal
monitoring and smart data management for Livestock and Companion
Animals. In March 2019, Merck Animal Health acquired Scan Aqua AS,
a fish health and fish welfare company based in Norway, focused on
key aquaculture products.
About Merck Animal Health
For more than a century, Merck, a leading global
biopharmaceutical company, has been inventing for life, bringing
forward medicines and vaccines for many of the world’s most
challenging diseases. Merck Animal Health, a division of Merck
& Co., Inc., Kenilworth, N.J., USA, is the global animal health
business unit of Merck. Through its commitment to The Science of
Healthier Animals®, Merck Animal Health offers veterinarians,
farmers, pet owners and governments one of the widest ranges of
veterinary pharmaceuticals, vaccines and health management
solutions and services as well as an extensive suite of digitally
connected identification, traceability and monitoring products.
Merck Animal Health is dedicated to preserving and improving the
health, well-being and performance of animals and the people who
care for them. It invests extensively in dynamic and comprehensive
R&D resources and a modern, global supply chain. Merck Animal
Health is present in more than 50 countries, while its products are
available in some 150 markets. For more information, visit
www.merck-animal-health.com or connect with us on LinkedIn,
Facebook, and Twitter at @MerckAH.
About Pentair plc
At Pentair, we believe the health of our world depends on
reliable access to clean, safe water. We deliver a comprehensive
range of smart, sustainable water solutions to homes, business and
industry around the world. Our industry leading and proven
portfolio of solutions enables our customers to access clean, safe
water. Whether it’s improving, moving or enjoying water, we help
manage the world’s most precious resource. Smart, Sustainable,
Water Solutions. For Life.
Pentair had revenue in 2018 of $3 billion, and trades under the
ticker symbol PNR. With approximately 110 locations in 30 countries
and 10,000 employees, we believe that the future of water depends
on us. To learn more, visit https://www.pentair.com/.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline products that
the products will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If
underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set
forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2018
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191217005828/en/
Merck Media: Noreen Verbrugge + 1 (973) 937-5450
Noreen.Verbrugge@merck.com
Pam Eisele +1 (267) 305-3558 Pamela.Eisele@merck.com
Merck Investors: Michael DeCarbo + 1 (908) 740-1807
Michael.DeCarbo@merck.com
Pentair Media: Rebecca Osborn + 1 (763) 656-5589
Rebecca.Osborn@pentair.com
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024